Upgrade Alert for Endo Pharmaceuticals (ENDP)
Endo Pharmaceuticals (NASDAQ:ENDP) was upgraded from Underperform to Neutral at Mizuho today. The stock closed yesterday at $16.68 on volume of 8.1 million shares, above average daily volume of 7.5 million.
Endo Pharmaceuticals (NASDAQ:ENDP) has potential upside of 395.2% based on a current price of $16.68 and analysts' consensus price target of $82.60. Endo Pharmaceuticals shares should first meet resistance at the 50-day moving average (MA) of $32.81 and find additional resistance at the 200-day MA of $57.17.
Endo Pharmaceuticals Holdings Inc. is a specialty pharmaceutical company with products that provide pain management. The Company researches, develops, produces, and markets both branded and generic pharmaceuticals. Endo's products include Percocet, Percodan, and Lidoderm.
In the past 52 weeks, Endo Pharmaceuticals share prices have been bracketed by a low of $12.56 and a high of $96.58 and closed yesterday at $16.68, 33% above that low price. In the last five trading sessions, the 50-day moving average (MA) has fallen 5.3% while the 200-day MA has slid 2%.
SmarTrend is monitoring the recent change of momentum in Endo Pharmaceuticals. Please refer to our Company Overview for the results of our proprietary technical indicators that have been scanning shares of Endo Pharmaceuticals in search of a potential trend change.
Keywords: analyst upgrades/downgrades Endo Pharmaceuticals